云顶新耀合作伙伴新桥生物与Visara宣布VIS-101 IIa期临床在湿性AMD取得积极顶线数据

云顶新耀
Mar 13

VIS-101是一款靶向VEGF-A/ANG-2的新型四价双特异性抗体,凭借其创新的四价设计,旨在成为治疗视网膜血管疾病的潜在同类最佳(Best-in-class)药物IIa期顶线数据显示,VIS-101在治疗湿性年龄相关性黄斑变性(湿性AMD)时,展示出起效迅速、强效持久的治疗反应患者平均最佳矫正视力(BCVA)改善超过10个ETDRS字母,中央视网膜厚度(CST)改善中位数在100-150μm...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10